BNP Paribas Financial Markets’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-310
| Closed | -$217 | – | 5448 |
|
|
2025
Q1 | $217 | Sell |
310
-47
| -13% | -$54 | ﹤0.01% | 5202 |
|
|
2024
Q4 | $428 | Buy |
+357
| New | +$593 | ﹤0.01% | 5188 |
|
|
2023
Q3 | – | Sell |
-310
| Closed | -$2.51K | – | 3919 |
|
|
2023
Q2 | $2.51K | Hold |
310
| – | – | ﹤0.01% | 3713 |
|
|
2023
Q1 | $2.17K | Sell |
310
-57
| -16% | -$343 | ﹤0.01% | 3629 |
|
|
2022
Q4 | $2.59K | Hold |
367
| – | – | ﹤0.01% | 3715 |
|
|
2022
Q3 | $5.58K | Sell |
367
-75
| -17% | -$1.24K | ﹤0.01% | 4242 |
|
|
2022
Q2 | $4.38K | Buy |
442
+122
| +38% | +$1.08K | ﹤0.01% | 3831 |
|
|
2022
Q1 | $4.61K | Sell |
320
-486
| -60% | -$13.8K | ﹤0.01% | 3861 |
|
|
2021
Q4 | $42.1K | Buy |
806
+185
| +30% | +$10.3K | ﹤0.01% | 3766 |
|
|
2021
Q3 | $36.2K | Buy |
621
+500
| +413% | +$32.6K | ﹤0.01% | 3581 |
|
|
2021
Q2 | $9.71K | Sell |
121
-295
| -71% | -$23.5K | ﹤0.01% | 3739 |
|
|
2021
Q1 | $34.6K | Sell |
416
-289
| -41% | -$29.3K | ﹤0.01% | 3687 |
|
|
2020
Q4 | $53.4K | Sell |
705
-17
| -2% | -$1.52K | ﹤0.01% | 3527 |
|
|
2020
Q3 | $77K | Sell |
722
-15,125
| -95% | -$2.1M | ﹤0.01% | 3253 |
|
|
2020
Q2 | $2.4M | Sell |
15,847
-2,701
| -15% | -$266K | ﹤0.01% | 1416 |
|
|
2020
Q1 | $1.55M | Buy |
18,548
+18,140
| +4,446% | +$2.55M | ﹤0.01% | 1626 |
|
|
2019
Q4 | $69K | Sell |
408
-4,923
| -92% | -$813K | ﹤0.01% | 3484 |
|
|
2019
Q3 | $990K | Buy |
5,331
+5,017
| +1,598% | +$970K | ﹤0.01% | 1849 |
|
|
2019
Q2 | $71.8K | Sell |
314
-338
| -52% | -$66.1K | ﹤0.01% | 3220 |
|
|
2019
Q1 | $137K | Buy |
652
+650
| +32,500% | +$122K | ﹤0.01% | 2930 |
|
|
2018
Q4 | $242 | Sell |
2
-83
| -98% | -$12.3K | ﹤0.01% | 4076 |
|
|
2018
Q3 | $19.6K | Sell |
85
-62
| -42% | -$13.7K | ﹤0.01% | 3419 |
|
|
2018
Q2 | $32.7K | Sell |
147
-504
| -77% | -$113K | ﹤0.01% | 3297 |
|
|
2018
Q1 | $149K | Sell |
651
-1,976
| -75% | -$519K | ﹤0.01% | 2978 |
|
|
2017
Q4 | $688K | Buy |
2,627
+2,367
| +910% | +$555K | ﹤0.01% | 2244 |
|
|
2017
Q3 | $58.3K | Sell |
260
-21
| -7% | -$5.16K | ﹤0.01% | 3071 |
|
|
2017
Q2 | $76.7K | Buy |
281
+274
| +3,914% | +$74.3K | ﹤0.01% | 2955 |
|
|
2017
Q1 | $1.67K | Sell |
7
-34
| -83% | -$7.77K | ﹤0.01% | 3580 |
|
|
2016
Q4 | $8.45K | Sell |
41
-142
| -78% | -$33.7K | ﹤0.01% | 3524 |
|
|
2016
Q3 | $49.9K | Buy |
183
+67
| +58% | +$14.8K | ﹤0.01% | 2431 |
|
|
2016
Q2 | $16.6K | Buy |
+116
| New | +$15.6K | ﹤0.01% | 2663 |
|
|
2016
Q1 | – | Sell |
-530
| Closed | -$114K | – | 2697 |
|
|
2015
Q4 | $114K | Hold |
530
| – | – | ﹤0.01% | 2247 |
|
|
2015
Q3 | $85.7K | Buy |
530
+326
| +160% | +$70.5K | ﹤0.01% | 2488 |
|
|
2015
Q2 | $52.7K | Buy |
204
+120
| +143% | +$28.7K | ﹤0.01% | 2464 |
|
|
2015
Q1 | $18.9K | Buy |
+84
| New | +$17.6K | ﹤0.01% | 2394 |
|
|
2014
Q4 | – | Sell |
-162
| Closed | -$34.8K | – | 2074 |
|
|
2014
Q3 | $34.8K | Buy |
162
+158
| +3,950% | +$30.7K | ﹤0.01% | 2815 |
|
|
2014
Q2 | $988 | Buy |
+4
| New | +$873 | ﹤0.01% | 3428 |
|
Other funds holding AXDX
BNP Paribas Financial Markets's AXDX Position: Q2 2025 in Review
BNP Paribas Financial Markets sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 310 shares — an estimated $217 sold.
BNP Paribas Financial Markets first reported a position in AXDX in Q2 2014 and held it in 37 quarters. The position peaked at $2.4M in Q2 2020. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.
- BNP Paribas Financial Markets reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 310 Accelerate Diagnostics shares in Q2 2025, an estimated $217.
- BNP Paribas Financial Markets first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 37 quarters.
- BNP Paribas Financial Markets's Accelerate Diagnostics position peaked at $2.4M in Q2 2020.
- 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2025, filed 14 Aug 2025.